High-Risk Subset of CLL Patients Shows Benefit in Phase II Trial

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

The University of Rochester Wilmot Cancer Institute last week was named the 73rd NCI-designated cancer center. Now, New York State has eight NCI-designated cancer centers. Only California has more—ten.

March 28, 2025

Vol.51 No.12

By Paul Goldberg

Capitol Hill

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

The U.S. Department of Health and Human Services announced that it is making sweeping revisions by cutting personnel, centralizing functions, and consolidating divisions.

March 28, 2025

Vol.51 No.12

By Claire Marie Porter and Jacquelyn Cobb

News Analysis

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated

The March 15 continuing resolution has gutted the Department of Defense Congressionally Directed Medical Research Program. The program’s funding was cut by 57%, compared to Fiscal Year 2024 levels—from $1.5 billion to $650 million.

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.

March 28, 2025

Vol.51 No.12

By W. Kimryn Rathmell

Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease.

March 28, 2025

Vol.51 No.12

By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie

Building a nationally integrated cancer research and treatment network

Cancer care is at an inflection point. The traditional boundaries between academic and community oncology are dissolving, requiring a reimagined approach to patient care and clinical research. At City of Hope, we are implementing a national model that integrates breakthrough research with accessible, advanced treatment across diverse geographic regions.

March 28, 2025

Vol.51 No.12

By Edward S. Kim

High-Risk Subset of CLL Patients Shows Benefit in Phase II Trial

YOU MAY BE INTERESTED IN

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

Building a nationally integrated cancer research and treatment network

Renew today!

Subscriber content

Never miss an issue!

Login

High-Risk Subset of CLL Patients Shows Benefit in Phase II Trial

YOU MAY BE INTERESTED IN

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hitAlso this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

DOD cancer research programs face 57% funding cut in year-long continuing resolutionPancreatic, lung, kidney cancer research programs eliminated

Rathmell: We must support our junior colleagues“Empathy and listening is a key place to start”

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunityWeill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

Building a nationally integrated cancer research and treatment network

Never miss an issue!

Login

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration